Updated heart failure management guidelines add recommendations for the use of SGLT inhibitors and for managing patients with cancer therapy-related cardiotoxicity.
A human genetics experts discusses how these DNA tests might be useful in practice and what cautions remain.
A team explores the possible association between genetic variants in the human genome and liver attenuation.
People whose blood pressure is hard to control might have another condition that’s the real culprit. So why aren’t they being tested for primary aldosteronism?
Preclinical study identifies possible therapeutic target for cardiovascular risk factors that avoid the common problem of an increased risk of fatty liver disease.
New findings give reason to pay attention to metabolic dysfunction well before middle age.